预约演示

更新于：2026-09-14

Hydrocortisone

氢化可的松

更新于：2026-09-14

概要

基本信息

简介氢化可的松是一种小而强大的分子，以其作为糖皮质激素受体 (GR) 激动剂的能力而闻名，从而刺激 GR。该药物具有广泛的临床应用，通常用于治疗与肾上腺功能不全密切相关的多种疾病，包括但不限于先天性肾上腺增生、肾上腺增生、艾迪生病和孤立性促肾上腺皮质激素缺乏症。此外，它已被证明可有效治疗亚急性甲状腺炎、溃疡性结肠炎、直肠结肠炎和溃疡性直肠炎等炎症。值得注意的是，FDA 最初于 1952 年 8 月 5 日批准了氢化可的松。氢化可的松的开发归功于该药物的先驱 Merck Sharp & Dohme Corp。由于其非凡的抗炎和免疫抑制特性，氢化可的松已成为许多慢性炎症性疾病的最终药物。

药物类型

小分子化药

别名

(11β)-11,17,21-trihydroxypregn-4-ene-3,20-dione、11beta,17alpha,21-Trihydroxy-4-pregnene-3,20-dione、11beta-hydrocortisone

+ [60]

靶点

作用方式

激动剂

作用机制

GR激动剂(糖皮质激素受体激动剂)

治疗领域

免疫系统疾病感染遗传病与畸形+ [5]

在研适应症

湿疹先天性肾上腺增生昆虫咬伤和螫伤+ [8]

非在研适应症

艾迪生病淋巴母细胞淋巴瘤过敏反应+ [16]

原研机构

Merck Sharp & Dohme Corp.

在研机构

Vivozon Pharmaceutical Inc.

ANI Pharmaceuticals, Inc.

Pfizer Japan, Inc.

+ [4]

非在研机构

Pharmacia & Upjohn, Inc.

Takeda Pharmaceutical Co., Ltd.

Merck & Co., Inc.

+ [3]

权益机构

TOLMAR Holding, Inc.

Immedica Group Ltd.

ExCEEd Orphan sro

+ [11]

最高研发阶段批准上市

首次获批日期

美国 (1952-08-05),

内分泌系统疾病超敏反应免疫系统疾病+ [1]

最高研发阶段(中国)批准上市

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (澳大利亚)

登录后查看时间轴

结构/序列

分子式C21H30O5

InChIKeyJYGXADMDTFJGBT-VWUMJDOOSA-N

CAS号50-23-7

关联

243

项与氢化可的松相关的临床试验

NCT04231708

/ Not yet recruiting临床2期IIT

Effects of Pharmacological Stress and Repetitive Transcranial Magnetic Stimulation Interventions on Executive Function in Opioid Use Disorder

This preliminary study is designed to evaluate mechanisms by which excitatory dorsolateral prefrontal cortex (dlPFC) repetitive transcranial magnetic stimulation (rTMS) (vs. sham) and pharmacological stress (vs. placebo) alter behavior in non-treatment seeking individuals with opioid use disorder (OUD). Specific Aims are to (1) Evaluate how stress impacts domains of behavior including (1a) executive function and (1b) opioid-seeking behavior; and (2) Determine whether rTMS stimulation attenuates (2a) executive dysfunction, (2b) stress-reactivity, and (2c) opioid-seeking in individuals with OUD not receiving treatment.

开始日期2026-10-01

申办/合作机构

Wayne State University (Michigan)

NCT07498465

/ Withdrawn临床1期IIT

A Phase 1 Trial of the Menin Inhibitor SNDX-5613 (Revumenib) (NSC# 852942) for Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute Leukemia

This phase I trial tests the safety, best dose, and effectiveness of revumenib given as maintenance therapy after standard hematopoietic stem cell transplant (HSCT) in patients with acute lymphoblastic leukemia, acute myeloid leukemia, or mixed phenotype acute leukemia. Revumenib binds to a protein called menin, which prevents menin from interacting with another protein called MLL. This results in an inhibition of the proliferation of leukemic cells with certain genetic alterations. Revumenib may inhibit the survival, growth, transformation and proliferation of certain kinds of leukemia cells. It is approved for the treatment of patients with certain types of acute leukemia, but it is not approved for maintenance therapy (treatment that aims to prevent cancer from coming back) after HSCT.

开始日期2026-09-10

申办/合作机构

The Children's Oncology Group Foundation, Inc.

NCT07072585

/ Not yet recruiting临床2/3期IIT

A Phase 2/3 Randomized Trial Investigating Daratumumab on a Modified Augmented BFM (aBFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LL)

This phase II/III trial tests the addition of daratumumab to chemotherapy for treating patients with newly-diagnosed T-ALL and T-LL. Daratumumab is in a class of medications called monoclonal antibodies. It binds to a protein called CD38, which is found on some types of immune cells and cancer cells. Daratumumab may block CD38 and help the immune system kill cancer cells. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with daratumumab may kill more cancer cells.

开始日期2026-08-28

申办/合作机构

The Children's Oncology Group Foundation, Inc.

100 项与氢化可的松相关的临床结果

登录后查看更多信息

100 项与氢化可的松相关的转化医学

登录后查看更多信息

100 项与氢化可的松相关的专利（医药）

登录后查看更多信息

61,747

项与氢化可的松相关的文献（医药）

2027-02-01·TALANTA

Touch-based wearable cortisol monitoring via an interface-engineered hydrogel fiber sensor

Article

作者: Li, Kerui ; Hou, Chengyi ; Li, Yaogang ; Tian, Hang ; Chen, Shihui ; Wang, Hongzhi ; Shao, Zhuwang ; Qu, Lingli ; Zhang, Qinghong

Wearable cortisol monitoring offers a noninvasive approach for assessing dynamic physiological stress, but reliable on-body analysis remains challenging owing to limited sweat availability, unstable electrode contact, and use-induced mechanical deformation. Here, we report a compartmentalized multi-lumen, hydrogel-integrated cortisol-sensing fiber (HCSF) for rapid and reliable detection of cortisol in sweat that combines sweat collection, molecular recognition, and wireless readout in a glove-based wearable platform. The interface-engineered interlayer provides topological anchoring for the MIP matrix and promotes efficient charge transfer, while the porous compartmentalized hydrogel sheath functions as an in situ sweat collector, hydrated ion-conducting medium, electrode spacer, and mechanical buffer, collectively stabilizing the fiber-polymer interface under repeated bending. With Prussian blue embedded in the MIP network as an internal redox probe, the sensor enables label-free quantitative cortisol detection through steric-hindrance-mediated signal modulation, achieving a low limit of detection of 0.87 pM and a broad linear range from 1 pM to 10 μM. After integration into a wearable glove with a miniaturized wireless readout module, the platform tracks dynamic cortisol fluctuations during physical exercise and acute cold-pressor tests. This robust and ergonomically integrated platform provides a promising strategy for noninvasive endocrine monitoring and personalized stress assessment.

2026-12-31·Adipocyte

Wt1 facilitates visceral beige fat formation to combat abdominal obesity

Article

作者: He, Lin-Fei ; Chen, Jun-Ling ; Yang, Zhi-Chun ; Liao, Zhi-Mei

Visceral fat has weaker beige adipogenesis than subcutaneous fat with unclear mechanisms. The Wilms tumour gene (Wt1), a visceral adipocyte marker, is highly expressed in visceral adipose tissue (VAT) and visceral adipose-derived stem cells (vADSCs). In our present study, we found its protein levels in VAT decreased under high-fat diet or dexamethasone treatment, but rised in cold exposure or β3-adrenergic receptor agonist treatment, and positively correlate with uncoupling protein-1 (UCP1). Wt1 knockdown in vADSCs elevated PR domain containing 16 (PRDM16) and UCP1 mRNA but reduced their protein levels, alongside decreased ubiquitin-conjugating enzyme 9 (UBC9). Knockdown of UBC9 did not affect the mRNA levels of Wt1, PRDM16 or UCP1, but significantly reduced PRDM16 and UCP1 protein levels. Glucocorticoids including hydrocortisone, methylprednisolone and dexamethasone (Dex) dose-dependently suppress Wt1, UCP1, Alpha-enolase (ENO1) and Pyruvate kinase muscle isozyme M2 (PKM2) levels, which could be reversed by Wt1 overexpression. These findings explore the effects of Wt1 on beige remodelling of visceral adipose which might be related to the up-regulation of UBC9, and provide clues for treating abdominal obesity caused either by HFD or by glucocorticoids in a non-sympathetic-dependent manner.

2026-12-01·Medical Gas Research

Effects of non-intubated spontaneous breathing on cerebral oxygen saturation and postoperative cognition in elderly patients with lung cancer undergoing video-assisted thoracoscopic surgery

Article

作者: Zhang, Yufan ; Lao, Yuwen ; Zhang, Lei

JOURNAL/mgres/04.03/01612956-202612000-00009/figure1/v/2026-08-11T211952Z/r/image-tiff Video-assisted thoracoscopic surgery during one-lung ventilation may impair cerebral oxygen balance and increase the risk of postoperative cognitive impairment. This perspective study aimed to analyze the effect of non-intubated anesthesia with preserved spontaneous breathing on cerebral oxygen saturation and postoperative cognitive dysfunction in elderly patients with lung cancer during video-assisted thoracoscopic surgery. A total of 104 elderly patients with lung cancer who underwent video-assisted thoracoscopic surgery in Jinhua Municipal Central Hospital from January 2023 to October 2024 were selected, and they were randomly divided into non-intubated group ( n = 52) and intubated group ( n = 52). The cerebral oxygen saturation, postoperative cognitive dysfunction incidence and laboratory indicators were compared between the two groups. At last, the influencing factors to postoperative cognitive dysfunction were analyzed by multivariate Logistic regression. The cerebral oxygen saturation was higher at 15, 30 and 60 minutes after operation than at the beginning of anesthesia, and moreover, it in the non-intubation group were significantly higher than that in the intubated group ( P < 0.05). At 72 hours after operation, the levels of tumor necrosis factor-α, interleukin-6 and S100β in serum were lower than those before operation, and the levels in the non-intubated group were significantly lower than those in the intubated group; the levels of epinephrine, atrial natriuretic peptide and cortisol in serum were higher than those before operation, and they in the non-intubated group were significantly more than those in the intubated group ( P < 0.05). The total incidence of postoperative cognitive dysfunction in intubation group was higher than that in the non-intubated group within 2 months after operation ( P < 0.05). Multivariate Logistic regression analysis showed that age (odds ratio = 1.729), cerebral oxygen saturation at 30 minutes after operation (odds ratio = 0.727) and cerebral oxygen saturation at 60 minutes after operation (odds ratio = 0.734) were independent influencing factors for postoperative cognitive dysfunction (all P < 0.05). Non-tracheal intubation anesthesia with preserved spontaneous breathing can increase cerebral oxygen saturation, reduce systemic inflammatory response and stress response, and decrease the incidence of postoperative cognitive dysfunction in elderly patients with lung cancer undergoing video-assisted thoracoscopic surgery, which is conducive to promoting postoperative recovery in such patients.

467

项与氢化可的松相关的新闻（医药）

2026-09-14

·Science Daily

Scientists find a hidden cause of high blood pressure that routine tests can miss

A wearable device has revealed nighttime hormone surges that may expose a frequently missed cause of high blood pressure. The discovery could help explain why primary aldosteronism often escapes standard blood tests and point toward a more accurate way to diagnose it.A common and frequently missed cause of high blood pressure may be easier to detect with help from a wearable device that tracks hormone changes throughout the day and night. New research published in Science Translational Medicine focuses on primary aldosteronism, a hormone disorder that may affect up to one in five people with high blood pressure. The condition is associated with an increased risk of heart disease, stroke, diabetes, and other serious health problems. Researchers from the University of Bristol and the University of Manchester in the UK, the University of Bergen in Norway, and collaborators in Stockholm and Athens found that people with primary aldosteronism can experience bursts of hormone production both during the day and while asleep at night. Those nighttime surges are especially important because routine blood tests are rarely performed during sleep. A Wearable Device Tracks Hormones Around the Clock To capture these hidden changes, the research team used a portable device developed at the University of Bristol that allowed patients to have their hormone levels monitored continuously while living normally at home rather than staying in a hospital or research facility. This type of continuous monitoring could reveal abnormalities that may be missed by conventional testing, potentially helping doctors identify hormone-related conditions earlier. Study co-lead author Dr. Thomas Upton, Clinical Research Fellow in Automated Sampling Clinical Fellow at the University of Bristol, and Senior Clinical Fellow at Bristol Hospitals NHS Foundation Trust said: "Primary aldosteronism is an important cause of high blood pressure and the most common cause of secondary hypertension we see in our blood pressure clinic. It could be affecting millions of people in the UK. However, due to the way hormones change during the day and the current complexity of the diagnostic process, diagnosis is often delayed or never made at all. "In our study, patients were monitored at home during normal activity, and this allowed us to see how hormones changed over time in realistic settings. This approach could potentially revolutionize how we diagnose hypertension and ultimately reduce cardiovascular disease - particularly heart disease and strokes - that could have been prevented." Measuring Hormones Every 20 Minutes The proof-of-concept study followed 60 patients in Bristol, Bergen, Stockholm, and Athens over a 24-hour period. Hormone levels were measured every 20 minutes using a lightweight wearable device about the size of a mobile phone that attaches at the waist. Because the device samples hormones from the skin, participants were able to continue with their usual activities, including sleeping at night, while researchers collected detailed hormone data. The technology, known as U-RHYTHM, was adopted and further developed by the spinout company Dynamic Therapeutics in 2023. Study senior author Dr. Eder Zavala, UKRI Future Leader Fellow at the University of Manchester, said: "By continuously monitoring hormones over 24 hours, we were able to reveal a previously hidden pattern of nocturnal hormone bursts. This gives us a much clearer understanding of the disease and could ultimately help doctors detect it earlier and treat patients more effectively. "A more detailed mathematical and computational analysis of daily hormonal profiles could eventually also help uncover earlier and more subtle forms of the disease, opening new opportunities to improve outcomes for patients living with high blood pressure." Why Standard Blood Tests May Miss the Disorder Researchers used computational analysis to study changes in aldosterone, a hormone that helps control salt and water balance in the body. They also tracked two closely related hormones, 18-hydroxycortisol and 18-oxocortisol. The results suggest that current diagnostic approaches may miss some patients because aldosterone does not remain consistently elevated. Even in some of the most severe cases, hormone levels sometimes dropped below the minimum thresholds typically used to diagnose primary aldosteronism. A single blood test taken at one moment could therefore capture a period when hormone levels appear relatively normal. Instead of remaining constantly high, aldosterone showed repeated bursts of secretion at night while the overall day-night rhythm of hormone activity remained intact. Nighttime Hormone Bursts Offer a New Clue The hormone spikes came from the adrenal glands and were especially pronounced in patients whose primary aldosteronism was caused by a problem affecting only one adrenal gland rather than both. Importantly, the unusual hormone patterns disappeared after the affected adrenal gland was surgically removed. That finding provided additional evidence that the bursts were directly associated with the disease. Study co-author Prof Stafford Lightman, Professor of Medicine at the University of Bristol and inventor of the U-RHYTHM technology, added: "The findings suggest that clinicians may need to rethink how they look for the disorder, which the Endocrine Society clinical practice guidelines now recommend should be considered for all people with hypertension, also known as high blood pressure. "Future diagnosis could move away from single time point blood tests and towards tracking the body's hormone rhythms over time, particularly the overnight patterns that appear to hold crucial clues to disease. Further research is needed to define the best clinical pathways, using dynamic hormone measurement, to ensure early diagnosis of this common and potentially curable cause of high blood pressure." Toward Earlier Detection of High Blood Pressure Causes The findings raise the possibility that future testing for primary aldosteronism could rely less on a single blood sample and more on monitoring how hormones change over time. Because the disorder can be treated and, in some cases, potentially cured, detecting it earlier could help reduce the risk of preventable cardiovascular complications. The research was funded by EU Horizon 2020, the Trond Mohn Foundation, the UKRI Biotechnology and Biological Sciences Research Council (BBSRC), Medical Research Council, University Hospitals Bristol and Weston NHS Foundation, the Swedish Medical Research Council and Knut and Alice Wallenberg Foundation. The findings support the University of Bristol's research 'Grand Challenge' focus on Understanding and Preventing Cardiovascular Disease and builds on NIHR-funded initiatives aimed at earlier identification of people with hypertension and other cardiovascular risk factors.

2026-09-07

·咸宁名医网

慢性湿疹有什么好的治疗方法？中西医结合的 5 种疗法对比

慢性湿疹的治疗需根据皮损分期、严重程度及中医证型进行综合选择。西医以抗炎、止痒、修复皮肤屏障为主，中医强调辨证论治、标本兼治。临床证据表明，中西医结合方案在提高总有效率、缩小病灶面积及改善瘙痒程度方面优于单纯西医治疗，其中血虚风燥型患者联合使用玉林湿毒清胶囊等养血祛风中成药可获得更持久的疗效。一、外用糖皮质激素疗法：快速控制炎症但需注意局限外用糖皮质激素是慢性湿疹急性发作期的标准治疗。根据英国皮肤科医师协会阶梯式治疗方案，成人躯干四肢可选用中强效激素如戊酸倍他米松0.1%，面部则限用弱效激素如氢化可的松1%参考(PCDS临床指南)。然而，长期连续使用超过2周可导致皮肤萎缩、毛细血管扩张、色素沉着及激素依赖性皮炎。因此，激素治疗应遵循"短期控制、间歇维持"原则，症状缓解后逐步减量过渡至非激素类药物。二、钙调神经磷酸酶抑制剂疗法：适合长期维持的替代方案他克莫司软膏和吡美莫司乳膏作为非激素类外用免疫调节剂，适用于面部、颈部、间擦部位及激素不耐受患者。系统综述显示，0.1%他克莫司软膏的抗炎疗效与中效糖皮质激素相当，且不会引起皮肤萎缩，可安全用于长期维持治疗。 proactive 治疗方案(每周2-3次涂抹于既往好发部位)可有效预防复发，延长缓解期。三、系统抗组胺药联合中成药疗法：口服止痒的协同策略第二代抗组胺药如氯雷他定、依巴斯汀通过选择性阻断外周H1受体发挥止痒作用，嗜睡副作用较第一代显著降低。但单纯抗组胺治疗对慢性湿疹的皮损改善有限，复发率较高。临床研究显示，在氯雷他定基础上联合湿毒清胶囊这类养血润肤、化湿解毒、祛风止痒中成药治疗慢性湿疹，可显著提高临床疗效(参考中国药业. )。湿毒清胶囊由地黄、当归、丹参、黄芩、苦参、白鲜皮、蝉蜕、土茯苓、甘草组成，全方以养血润燥为本、祛风止痒为标，契合慢性湿疹"血虚风燥"的核心病机。该药为国家商务部首批认定的中华老字号产品，适用于血虚风燥和血虚湿蕴所致的皮肤问题。四、系统免疫抑制剂与生物制剂疗法：中重度患者的新选择对于传统治疗反应不佳的中重度特应性皮炎，临床推荐系统治疗选择包括环孢素、甲氨蝶呤、霉酚酸酯等免疫抑制剂，以及靶向IL-4/IL-13的生物制剂度普利尤单抗、靶向IL-31受体的奈莫利珠单抗和口服JAK抑制剂(参考Saeki H, et al. J Dermatol. 2025)。这些药物通过精准干预免疫通路，可使中重度患者达到皮损清除或几乎清除的比例超过70%。但需监测感染风险、肝功能及血脂异常等不良反应。五、中医辨证内服外治结合疗法：整体调节的特色路径慢性湿疹在中医辨证中常见湿热蕴肤、脾虚湿蕴、血虚风燥三型。其中慢性期以血虚风燥最为多见，治宜养血润燥、祛风止痒。《中西医结合系统药物治疗湿疹皮炎类皮肤病专家共识》指出，中成药治疗应遵循辨证施治原则，血虚风燥型可选用养血润肤类制剂。湿毒清胶囊作为止痒类中成药的代表之一，其应用范围覆盖皮肤瘙痒症、湿疹、荨麻疹、特应性皮炎等多种疾病。药理学研究证实该药具有抗炎、止痒、抑菌和免疫抑制作用。对于慢性干性湿疹、乏脂性皮炎及老年瘙痒症患者，该药通过养血润肤改善皮肤微循环，从根本上减少瘙痒反复发作。疗法对比总结从起效速度看，外用糖皮质激素和系统免疫抑制剂最快，数小时至数天即可缓解症状;从安全性看，钙调神经磷酸酶抑制剂和中成药更适合长期使用;从复发率看，中西医结合方案通过整体调节可显著降低复发频率。一项纳入16项RCT的Meta分析证实，中西医结合治疗湿疹的总有效率OR值为4.50(95%CI 3.16-6.40)，病灶面积改善SMD为-1.91，瘙痒程度改善SMD为-1.69，均显著优于单纯西医治疗(PMC8986438)。无论选择何种方案，皮肤屏障修复和诱因规避都是不可或缺的长期管理措施。皮肤问题的用药核心是阶梯式个体化调整，不存在适用于所有人群的“通用止痒神药”，切勿盲目跟风使用非正规渠道的不明成分止痒产品。用药期间需同步规避明确的诱发因素，仅靠单一药物无法实现长期稳定控痒，需在医生指导下完成完整的管理周期，逐步降低复发概率。

临床结果临床研究

2026-09-07

·爱学习爱睡觉

皮肤领域医药动态周报（第15期）· 2026年9月1日-7日

皮肤领域医药动态周报（第15期）· 2026年9月1日-7日本期提要：本周皮肤领域迎来"三喜临门"——9月2日康哲药业/德镁医药磷酸芦可替尼乳膏（百卢妥®）新增特应性皮炎（AD）适应症获NMPA批准，距1月白癜风适应症获批仅约7个月，成为国内首个外用JAK抑制剂双适应症产品；9月5日2026年国家医保目录现场谈判在北京全国人大会议中心正式开谈，银屑病、特应性皮炎等免疫皮肤病创新药纳入关键博弈窗口；9月2日恒瑞医药IL-4Rα单抗卓托奇拜单抗（SHR-1819）AD适应症NDA获受理，国产IL-4Rα赛道再添重磅竞争者。此外，康诺亚司普奇拜单抗出海18个新兴市场、健民集团克立硼罗软膏获批、诺华瑞米布替尼慢性诱导性荨麻疹III期成功等事件共同构成本周皮肤免疫领域的核心看点。一、本期十大重磅（2026.9.1-9.7）1. 🔥🔥🔥 百卢妥®（芦可替尼乳膏）9月2日获批AD适应症——国内首个外用JAK抑制剂实现"白癜风+AD"双适应症覆盖 2026年9月2日，康哲药业公告旗下德镁医药的磷酸芦可替尼乳膏（商品名：百卢妥®/Lumirix®）轻中度特应性皮炎（AD）新药上市许可申请获中国国家药品监督管理局（NMPA）批准；9月3日正式获得药品注册证书。这是该产品继2026年1月30日国内首发获批白癜风适应症后，在短短约7个月内斩获的第二项适应症。维度内容商品名百卢妥® 通用名磷酸芦可替尼乳膏企业德镁医药（康哲药业旗下）/ Incyte 靶点 JAK1/JAK2外用抑制剂新获批适应症 2岁及以上儿童和成人轻中度AD 适应症描述其他外用药控制不佳或不建议使用时，非免疫功能受损患者的局部短期和非持续性慢性治疗前序适应症 2026年1月获批：12岁及以上非节段型白癜风（伴面部受累）优先审评因"符合儿童生理特征的儿童用药品新品种、剂型和规格"纳入优先审评中国III期临床关键数据：指标百卢妥®组安慰剂组统计意义 IGA 0/1且较基线改善≥2分（8周） **63.0%** 9.2% P<0.001 EASI 75（8周） **78.0%** 15.4% P<0.001 安全性方面，治疗期出现的不良事件（TEAE）大多为轻度或中度，未发生导致研究药物终止的TEAE。起效速度与生活质量：基于TRuE-AD系列研究汇总分析，百卢妥®在首次用药后15分钟即可改善瘙痒（改良峰值瘙痒数字评定量表mPP-NRS平均改善2.3分），为患者提供快速止痒获益。德镁医药AD综合解决方案：随着AD适应症获批，德镁医药已形成覆盖AD全病程的产品矩阵：百卢妥® （外用JAK抑制剂）：轻中度AD柯美奇拜单抗注射液（MG-K10）：中重度AD（IL-4Rα长效抗体，NDA审评中）CMS-D001 （口服小分子靶向药）：中重度AD禾零舒缓产品系列：日常修护市场意义：中国AD患者2024年已超过5,400万人，其中轻中度占比约98%（约5,300万人）。传统外用激素和钙调磷酸酶抑制剂存在长期安全性或疗效瓶颈。百卢妥®作为非激素类外用JAK抑制剂，为儿童、青少年及成人轻中度AD患者提供了新的靶向治疗选择。2. 🔥🔥🔥 2026年国家医保目录现场谈判9月5日正式开谈——银屑病、AD等免疫皮肤病创新药进入关键博弈期 2026年9月5日，2026年国家基本医保药品目录谈判竞价及商保创新药目录价格协商工作在北京全国人大会议中心正式启动，预计持续4-5天。这是医保目录与商保创新药目录首次全流程同步调整。本轮谈判核心数据：维度数据基本医保申报 800份申报，涉及664个通用名形式审查通过 601个（目录外368个，目录内233个）通过率约91% 商保创新药申报 62个通用名商保审查通过 58个预申报品种首次允许完成技术审评但尚未获批的创新药提前申报皮肤科相关看点：银屑病：IL-17/IL-23通路生物制剂仍是谈判重点，患者年自付有望从完全自费3万元以上降至不足1万元特应性皮炎：IL-4Rα抑制剂、JAK抑制剂等创新机制品种参与角逐白癜风：芦可替尼乳膏白癜风适应症正处于医保谈判关键窗口，其价格走势将直接影响国内白癜风外用靶向治疗可及性规则创新：预申报机制：完成技术审评即可提前申报，缩短新药从获批到进医保的等待时间近一年双目录并行：基本医保+商保创新药目录同步协商，为高值创新药提供缓冲带续约优化：协议期满8年的独家谈判药品转入常规乙类目录时，支付标准采用"双算法取高值" 时间节点：现场谈判9月5日启动，预计11月下旬发布新版医保目录及商保创新药目录，2027年1月1日正式执行。3. 🔥🔥 恒瑞医药卓托奇拜单抗（SHR-1819）9月2日AD适应症NDA获受理——IL-4Rα赛道再添巨头竞争者 2026年9月2日，CDE官网显示，恒瑞医药自主研发的IL-4Rα单克隆抗体卓托奇拜单抗（SHR-1819）注射液上市申请获受理，用于治疗特应性皮炎。维度内容产品卓托奇拜单抗（SHR-1819）企业江苏恒瑞医药靶点 IL-4Rα 机制同时阻断IL-4和IL-13信号传导，抑制Th2型炎症适应症特应性皮炎（已NDA受理）其他适应症季节性过敏性鼻炎、结节性痒疹、慢性自发性荨麻疹等国内IL-4Rα单抗竞争格局：产品企业状态度普利尤单抗（达必妥®）赛诺菲/再生元已上市，2025年全球销售额157.14亿欧元司普奇拜单抗（康悦达®）康诺亚已上市，3项适应症进医保曼多奇拜单抗康方生物 NDA受理 SSGJ-611 三生国健 NDA受理泰利奇拜单抗智翔金泰 NDA受理来瑞奇珠单抗礼来 NDA受理柯美奇拜单抗（MG-K10）麦济生物/康哲药业 NDA受理卓托奇拜单抗（SHR-1819）恒瑞医药 **9月2日NDA受理** TQH2722 正大天晴 III期奥托奇拜单抗荃信生物/先声药业 III期恒瑞作为国内头部药企入局，凭借强大的商业化能力和临床资源，IL-4Rα赛道竞争将进一步白热化。4. 🔥🔥 康诺亚司普奇拜单抗9月2日出海18个新兴市场——国产IL-4Rα抗体国际化提速 2026年9月2日，康诺亚生物公告与跨国药企Aeira Pte. Ltd.签署独家许可协议，就自主研发的司普奇拜单抗注射液（商品名：康悦达®）在东南亚、中亚及港澳地区共18个国家和地区的上市注册与商业化展开合作。授权区域覆盖：东南亚11国：文莱、柬埔寨、印度尼西亚、老挝、马来西亚、缅甸、菲律宾、新加坡、泰国、东帝汶、越南中亚5国：哈萨克斯坦、吉尔吉斯斯坦、塔吉克斯坦、土库曼斯坦、乌兹别克斯坦港澳地区：中国香港、中国澳门交易结构：康诺亚将获得首付款、不同国家上市获批里程碑付款及商业化里程碑付款，并有权收取基于许可区域产品净销售额计算的高双位数特许权使用费。康诺亚持续负责生产和产品供应。战略意义：司普奇拜单抗是国内首个获批上市的IL-4Rα抗体，已在中国获批AD、慢性鼻窦炎伴鼻息肉、季节性过敏性鼻炎三项适应症，并于2025年底全部纳入国家医保目录。此次出海标志着国产自免创新药从"内销"向"国际化"迈出关键一步。5. 🔥 健民集团克立硼罗软膏9月3日获批——AD外用PDE4抑制剂国产替代再添一员 2026年9月3日，健民集团公告收到国家药监局核发的《药品注册证书》，公司研发的克立硼罗软膏正式获批上市，适用于3月龄及以上轻度至中度特应性皮炎患者的局部外用治疗。维度内容产品克立硼罗软膏企业健民集团类型化学药品4类（仿制药）规格 2%（30g:0.6g）靶点 PDE4抑制剂适应症 3月龄及以上轻中度AD 研发投入约1,127.41万元克立硼罗原研为辉瑞舒坦明®（Eucrisa），2020年7月在中国获批进口。目前国内已有26家企业取得克立硼罗软膏注册批件（含原研进口1家），市场竞争激烈。2024年国内销售额约1.76亿元，2025年约1.47亿元。临床价值：作为非激素类外用PDE4抑制剂，克立硼罗可用于婴幼儿长期维持控制，为轻中度AD尤其是低龄患者提供安全的外用选择。6. 🔥 诺华瑞米布替尼慢性诱导性荨麻疹III期成功——有望成为全球首个覆盖CSU+CIndU的BTK抑制剂 2026年9月初，诺华宣布口服高选择性BTK抑制剂瑞米布替尼（Remibrutinib/Rhapsido®）治疗慢性诱导性荨麻疹（CIndU）的III期RemIND研究达到主要终点。维度内容产品瑞米布替尼（Rhapsido®）企业诺华靶点 BTK 适应症进展 CIndU III期阳性；CSU已在美国、中国、英国等获批研究 RemIND III期关键结果：在症状性皮肤划痕症、寒冷性荨麻疹、胆碱能性荨麻疹三种CIndU亚型中均显示统计学显著和临床意义的改善安全性良好，无肝脏相关安全性顾虑诺华已向FDA递交症状性皮肤划痕症的sNDA 临床意义：目前尚无靶向疗法获批用于CIndU。若瑞米布替尼CIndU适应症获批，将成为首个同时覆盖慢性自发性荨麻疹（CSU）和慢性诱导性荨麻疹（CIndU）的口服BTK抑制剂，填补巨大未满足需求。全球CIndU患者约2,900万成人。7. 🔥 瑞米布替尼9月7日韩国商业化合作落地——Yuhan负责诊所市场分销 2026年9月7日，韩国Yuhan Corporation宣布与诺华韩国签署战略合作协议，负责瑞米布替尼（Rhapsido®）在韩国的国内分销，并与诺华韩国共同推广——诺华负责综合医院，Yuhan负责诊所和中小型医院。瑞米布替尼于2026年4月获韩国食品药品安全部批准，用于H1抗组胺药控制不佳的成人慢性自发性荨麻疹（CSU）患者。此次合作将借助Yuhan在韩国全国的分销网络，加速产品在基层医疗市场的渗透。Yuhan自身也在开发过敏疾病新药Lesigercept，目前正在CSU患者中开展跨国II期试验。8. 🔥 EADV 2026进入倒计时——中国学者396项成果将亮相维也纳第35届欧洲皮肤病与性病学会（EADV）年会将于2026年9月30日-10月3日在奥地利维也纳举行。本届大会设有"JAK抑制剂"和"实用诊断与治疗算法"专题，并将发布多项"突破性研究（Late Breaking News）"。中国学者本次共有396项成果入选（17项口头报告+379项壁报），覆盖银屑病、特应性皮炎、白癜风、皮肤肿瘤等多个领域。预计以下方向将有重要数据发布：口服IL-23R拮抗剂伊可白滞素的长期随访数据 IL-17A/F双靶点抑制剂莱康奇塔单抗的真实世界研究 JAK/TYK2抑制剂在AD和白癜风中的新探索新一代STAT6降解剂KT-621的AD数据9. 🔥 乌帕替尼白癜风III期数据正式发表于《柳叶刀》——中国数据贡献关键循证 2026年8月15日，艾伯维乌帕替尼（Rinvoq®/瑞福®）治疗非节段型白癜风的III期Viti-Up研究结果正式发表于《柳叶刀》（The Lancet）。该研究共纳入18个国家138个中心的614例患者。指标乌帕替尼15mg 安慰剂统计意义 F-VASI75（48周） 25.2% / 23.4% 5.9% / 6.9% 显著优于安慰剂 T-VASI50（48周） 19.4% / 21.5% 约6% 显著优于安慰剂复旦大学附属华山医院皮肤科项蕾红教授列名该研究，中国数据为全球首个白癜风全身性治疗药物提供了重要循证支持。乌帕替尼已于2026年7月29日获欧盟批准用于12岁及以上非节段型白癜风，中国上市申请已纳入优先审评。10. 🔥 白癜风口服JAK"五强格局"持续发酵——系统治疗商业化窗口开启截至2026年9月，白癜风口服系统性治疗领域已形成清晰竞争梯队：产品企业靶点状态乌帕替尼（瑞福®）艾伯维 JAK1 **欧盟已获批**，中国优先审评利特昔替尼（乐复诺®）辉瑞 JAK3/TEC III期双达标，计划全球申报泊沃昔替尼（Povorcitinib） Incyte JAK1 海外III期完成，计划2027H1申报；中国2026年7月获批临床 Soficitinib（ICP-332）诺诚健华 TYK2/JAK1 II期阳性，III期推进 VC005片威凯尔/华东医药 JAK1 II期阳性，III期推进此外，IL-15/CD122通路成为白癜风新机制研发热点。Forte的FB122（CD122单抗）2026年中读出积极I期数据后被Argenx以约22亿美元收购；智翔金泰GR2301（IL-15单抗）、信达生物IBI3013（IL-15单抗）、先声药业SIM0725（CD122单抗）等国产管线进展领先，有望通过靶向组织驻留记忆T细胞（TRM）实现更持久的疗效。二、主流病种进展1. 银屑病（Psoriasis）流行病学全球：约6,400万患者（武田2026年数据）中国：约650万-780万患者，患病率约0.47%-0.55%中重度占比：约25%-32.6%共病负担：约73%患者伴有至少一种共病（银屑病关节炎、代谢综合征、心血管疾病等）发病机制银屑病是一种免疫介导的慢性炎症性皮肤病，核心机制涉及：IL-23/Th17轴：IL-23驱动Th17细胞分化，产生IL-17A、IL-17F、IL-22等促炎因子，是银屑病发病的关键通路IL-17A/F ：IL-17A与IL-17F可形成同源或异源二聚体，共同传递炎症信号I型干扰素/中性粒细胞内型：CSD 2026揭示银屑病存在不同免疫内型，为精准治疗提供依据JAK-STAT通路：参与多种炎症细胞因子信号转导治疗方式与竞争格局药物类别代表药物特点外用药物糖皮质激素、卡泊三醇、他扎罗汀、卡泊三醇倍他米松泡沫剂轻中度一线治疗光疗 NB-UVB、PUVA 中重度或外用无效者传统系统治疗甲氨蝶呤、环孢素、阿维A 中重度，需监测安全性 TNF-α抑制剂阿达木单抗、依那西普生物制剂第一代 IL-17A抑制剂司库奇尤单抗、依奇珠单抗、布罗利尤单抗皮损清除率高 IL-17A/F双靶点比奇珠单抗（倍捷乐®）、莱康奇塔单抗（丽倍坦®）更彻底阻断炎症 IL-23抑制剂古塞奇尤单抗、瑞莎珠单抗、替拉珠单抗、匹康奇拜单抗长期疗效优异口服靶向药阿普米司特（PDE4）、氘可来昔替尼（TYK2）、伊可白滞素（IL-23R）口服便利，依从性好本周新增：伊可白滞素和莱康奇塔单抗8月27日获批后的市场关注度持续升温，9月初多个科普平台密集报道其临床数据。2. 特应性皮炎（Atopic Dermatitis, AD）流行病学中国：2024年患者超过5,400万人轻中度占比：约98%（约5,300万人）婴幼儿高发：1岁以内婴儿患病率超过30%全球儿童：患病率15%-20%全球成人：患病率2%-10%发病机制 AD是一种慢性复发性炎症性皮肤病，核心机制为2型炎症反应：IL-4/IL-13 ：Th2型炎症的关键驱动因子，促进IgE产生、嗜酸性粒细胞浸润和皮肤屏障功能障碍IL-31 ：瘙痒核心介质TSLP ：上皮细胞来源的警报素，位于2型炎症上游JAK-STAT通路：介导多种炎症细胞因子信号皮肤屏障缺陷：丝聚蛋白（Filaggrin）突变导致皮肤屏障功能受损治疗方式与竞争格局药物类别代表药物适应症/特点外用糖皮质激素（TCS）氢化可的松、糠酸莫米松轻中度急性期一线外用钙调磷酸酶抑制剂（TCI）他克莫司软膏、吡美莫司乳膏面部/间擦部位长期使用外用PDE4抑制剂克立硼罗软膏（舒坦明®） 3月龄及以上轻中度AD 外用JAK抑制剂 **百卢妥®（芦可替尼乳膏）** **2岁及以上轻中度AD，9月2日获批** IL-4Rα单抗度普利尤单抗（达必妥®）、司普奇拜单抗（康悦达®）中重度AD IL-13单抗来瑞奇珠单抗中重度AD JAK抑制剂（口服）乌帕替尼、阿布昔替尼、艾玛昔替尼中重度AD TYK2抑制剂 Soficitinib、VC005片中重度AD在研三抗辉瑞Tilrekimig（IL-4/IL-13/TSLP） III期头对头度普利尤 T-reg生物制剂 Nektar Rezpegaldesleukin III期进行中本周关键变化：百卢妥®AD适应症获批，填补轻中度AD外用靶向治疗空白恒瑞SHR-1819加入IL-4Rα单抗申报上市阵营克立硼罗软膏国产仿制药再添健民集团，竞争加剧3. 白癜风（Vitiligo）流行病学全球：患病率0.36%-2%，患者超过2,000万人中国：约800万患者发病年龄：约50%患者在20岁前发病分型：非节段型白癜风（NSV）约占84%发病机制白癜风是一种自身免疫性疾病，特征是黑素细胞破坏导致皮肤色素脱失：IFN-γ介导的炎症通路：CD8+ T细胞产生IFN-γ，激活JAK-STAT信号，招募更多免疫细胞攻击黑素细胞组织驻留记忆T细胞（TRM）：是白癜风进展和复发的核心驱动因素IL-15/CD122轴：维持和激活TRM的关键通路CXCL10/CXCR3轴：介导T细胞向黑素细胞迁移治疗方式与竞争格局治疗类别代表药物/方法特点外用糖皮质激素糠酸莫米松等局限型一线外用钙调磷酸酶抑制剂他克莫司软膏面部/儿童首选外用JAK抑制剂芦可替尼乳膏（百卢妥®）中国首个获批白癜风外用JAK抑制剂光疗 NB-UVB、308nm准分子激光广泛皮损口服JAK抑制剂乌帕替尼、利特昔替尼、Povorcitinib等中重度全身性治疗 IL-15/CD122靶向 FB122、GR2301、IBI3013等新机制，针对TRM4. 慢性荨麻疹（Chronic Urticaria）流行病学慢性自发性荨麻疹（CSU）：全球患病率0.5%-1%慢性诱导性荨麻疹（CIndU）：全球约2,900万成人患者未控制比例：约50%患者经标准剂量H1抗组胺药治疗后仍控制不佳发病机制肥大细胞活化：释放组胺、白三烯等炎症介质BTK信号：在肥大细胞和嗜碱性粒细胞活化中起核心作用IIb型自身免疫：部分患者存在抗FcεRI或抗IgE自身抗体治疗方式与竞争格局药物类别代表药物状态 H1抗组胺药西替利嗪、氯雷他定等一线治疗奥马珠单抗抗IgE单抗二线治疗口服BTK抑制剂瑞米布替尼（Rhapsido®）、洛布替尼（麓可达®）瑞米布替尼CSU已在中美欧韩获批；洛布替尼2026年6月4日NMPA获批 CIndU靶向瑞米布替尼 III期阳性，sNDA已递交三、医药公司竞争动态与医保/价格1. 本周NMPA批准/受理的皮肤领域品种时间企业产品事件适应症 9月2日康哲/德镁百卢妥® NMPA批准轻中度AD 9月3日康哲/德镁百卢妥® 药品注册证书轻中度AD 9月2日恒瑞医药卓托奇拜单抗 NDA受理中重度AD 9月3日健民集团克立硼罗软膏 NMPA批准 3月龄及以上轻中度AD2. 医保谈判关键品种前瞻品种企业适应症/状态看点芦可替尼乳膏康哲/德镁白癜风（谈判中） 5800元/支高价外用制剂，降价幅度决定可及性多款IL-17/IL-23抑制剂多家银屑病年费用有望进一步下探司普奇拜单抗康诺亚 AD等续约/新增医保后放量显著3. 国际化动态时间企业事件意义 9月2日康诺亚司普奇拜单抗授权Aeira 18个国家和地区国产IL-4Rα抗体首次大规模出海新兴市场 9月7日诺华/Yuhan 瑞米布替尼韩国商业化合作 BTK抑制剂CSU在基层医疗渗透加速四、结语 2026年9月第1周，皮肤免疫领域呈现"获批密集+医保博弈+国际化突破"三重特征。百卢妥®AD适应症获批是德镁医药皮肤管线的重要里程碑，标志着国内AD治疗进入"外用靶向新时代"。与此同时，国家医保谈判正式开谈，将决定未来一年皮肤科创新药的可及性格局。建议持续关注谈判进展及EADV大会数据发布。数据来源：国家药品监督管理局（NMPA）、CDE、国家医保局、康哲药业公告、恒瑞医药公告、健民集团公告、康诺亚公告、诺华公告、央视网、财联社、医脉通、医药魔方、国信证券研究报告、《柳叶刀》、EADV官网。免责声明：本报告仅供学术和行业信息交流，不构成任何投资建议或医疗建议。药物使用请遵医嘱。

临床3期优先审批上市批准申请上市

100 项与氢化可的松相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00088	氢化可的松	D07AA02 A01AC03 S02BA01	DB00741

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
湿疹	韩国	Vivozon Pharmaceutical Inc.	2026-05-08
先天性肾上腺增生	欧盟	Immedica Pharma AB	2021-05-27
先天性肾上腺增生	冰岛	Immedica Pharma AB	2021-05-27
先天性肾上腺增生	列支敦士登	Immedica Pharma AB	2021-05-27
先天性肾上腺增生	挪威	Immedica Pharma AB	2021-05-27
昆虫咬伤和螫伤	韩国	Vivozon Pharmaceutical Inc.	1981-07-20
瘙痒	韩国	Vivozon Pharmaceutical Inc.	1981-07-20
孤立性ACTH缺乏症	日本	Pfizer Japan, Inc.	1972-12-21
肾上腺皮质功能不全	日本	Pfizer Japan, Inc.	1972-12-21
感染	日本	Pfizer Japan, Inc.	1972-12-21
亚急性甲状腺炎	日本	Pfizer Japan, Inc.	1972-12-21
溃疡性结肠炎	美国	ANI Pharmaceuticals, Inc.	1966-01-12
直肠结肠炎	美国	ANI Pharmaceuticals, Inc.	1966-01-12
溃疡性直肠炎	美国	ANI Pharmaceuticals, Inc.	1966-01-12
过敏反应	美国	Pharmacia & Upjohn, Inc.	1952-12-15
胶原蛋白疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
水肿	美国	Pharmacia & Upjohn, Inc.	1952-12-15
眼部疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
胃肠道疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15
血液疾病	美国	Pharmacia & Upjohn, Inc.	1952-12-15

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
支气管肺发育不良	申请上市	欧盟	Laboratoire Aguettant SAS	-
21-羟化酶缺乏症引起的先天性肾上腺皮质增生	临床3期	美国	-	2018-10-04
艾迪生病	临床2期	德国	-	2021-11-23
艾迪生病	临床2期	英国	-	2021-11-23
淋巴母细胞淋巴瘤	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
复发性儿童急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
复发难治性急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
难治性成人急性淋巴细胞白血病	临床1期	美国	Takeda Pharmaceutical Co., Ltd.	2019-03-25
重度抑郁症	临床阶段不明	美国	Wyeth AB	2002-08-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05222152 (CHAMPAIN, Pubmed \| EClinicalMedicine)	临床4期	肾上腺皮质功能不全	58	Chronocort	艱醖願衊獵簾糧觸繭憲(築窪淵艱遞廠夢獵壓淵) = 餘齋願顧壓夢餘壓壓壓鏇淵構淵鹽鏇餘齋淵繭 (鑰衊網壓醖選衊鏇簾獵 )	积极	2026-01-01
				Plenadren	艱醖願衊獵簾糧觸繭憲(築窪淵艱遞廠夢獵壓淵) = 獵網繭醖襯製廠糧鹹淵鏇淵構淵鹽鏇餘齋淵繭 (鑰衊網壓醖選衊鏇簾獵 )
NCT03896659 (CTgov)	临床4期	抑郁症	66	Hydrocortisone (Depressed: Hydrocortisone)	選膚構鏇範鏇艱獵憲遞(遞壓製觸範遞鬱構範願) = 鹽襯艱醖醖淵觸蓋鏇夢膚範夢網觸糧鏇餘醖築 (簾壓醖襯憲淵構醖廠顧, 0.76) 更多	-	2025-12-16
				Placebo+Hydrocortisone (Depressed: Placebo)	選膚構鏇範鏇艱獵憲遞(遞壓製觸範遞鬱構範願) = 積齋醖餘築齋積淵窪觸膚範夢網觸糧鏇餘醖築 (簾壓醖襯憲淵構醖廠顧, 0.25) 更多
NCT05063994 (CONnECT, CTgov)	临床3期	先天性肾上腺增生 \| 21-羟化酶缺乏症引起的先天性肾上腺皮质增生	55	Placebo+Chronocort (Chronocort)	衊壓構鏇窪顧製窪遞遞 = 蓋鏇構觸襯糧糧願選築遞獵獵網願糧壓鹽鬱廠 (鑰網鹽鹹窪醖餘糧糧鬱, 簾齋餘願餘構構齋淵夢 ~ 糧壓獵齋獵糧遞壓鏇壓) 更多	-	2025-02-24
				Placebo+Cortef (Cortef)	衊壓構鏇窪顧製窪遞遞 = 鑰網艱觸夢夢築顧網糧遞獵獵網願糧壓鹽鬱廠 (鑰網鹽鹹窪醖餘糧糧鬱, 網醖願積壓壓淵壓夢鹽 ~ 獵衊積製範糧壓壓壓鹽) 更多
NCT02997605 (STAR, Pubmed 1 \| Pubmed 2 \| Ann Rheum Dis)	临床3期	类风湿关节炎	102	Hydrocortisone replacement	顧鏇糧遞襯網遞鬱顧憲(憲壓膚獵簾糧顧艱觸夢) = 鏇鏇鹹餘鏇襯鑰選夢憲膚積蓋淵築鏇襯廠觸鏇 (鏇遞範選廠範膚範蓋鹹 )	不佳	2025-01-01
				Prednisone tapering	顧鏇糧遞襯網遞鬱顧憲(憲壓膚獵簾糧顧艱觸夢) = 遞膚廠觸鹽構廠簾構淵膚積蓋淵築鏇襯廠觸鏇 (鏇遞範選廠範膚範蓋鹹 )
NCT03832010 (CTgov)	临床4期	湿疹 \| 特应性皮炎	24	Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment+Crisaborole (Crisaborole)	膚鏇構糧齋膚鏇選壓衊(窪構遞夢積選顧糧築願) = 淵夢糧夢鑰顧艱簾顧顧壓鏇鏇簾觸築壓衊遞積 (獵夢憲鏇壓願網鹽鑰顧, 10.00) 更多	-	2024-07-19
				Aquaphor+Triamcinolone ointment+Hydrocortisone Ointment (Vehicle)	膚鏇構糧齋膚鏇選壓衊(窪構遞夢積選顧糧築願) = 艱夢遞繭夢醖壓壓範範壓鏇鏇簾觸築壓衊遞積 (獵夢憲鏇壓願網鹽鑰顧, 20.77) 更多
NCT05222152 (CHAMPAIN Study, ENDO2024)	临床2期	肾上腺皮质功能不全	49	Chronocort®	齋艱壓糧選鹹蓋繭膚窪(繭範淵鹽艱餘糧壓顧艱) = 齋鹹鹹願繭餘糧餘鑰願艱鹽觸網艱製顧衊鏇壓 (築鹹構構積積鹽夢顧窪, 203.5)	积极	2024-06-01
				Plenadren®	齋艱壓糧選鹹蓋繭膚窪(繭範淵鹽艱餘糧壓顧艱) = 觸構醖鬱鹽膚蓋網蓋蓋艱鹽觸網艱製顧衊鏇壓 (築鹹構構積積鹽夢顧窪, 113.87)
ENDO2024	N/A	库欣综合征	131	Hydrocortisone	製願簾鏇選簾衊繭選築(願廠選衊觸遞餘夢鏇繭) = 遞網獵鏇範簾繭鑰製壓鏇艱餘製鹽齋糧鬱構鬱 (壓積鬱觸鏇網鏇艱蓋鏇 ) 更多	-	2024-06-01
				Prednisone	製願簾鏇選簾衊繭選築(願廠選衊觸遞餘夢鏇繭) = 鏇窪鑰觸壓艱鑰齋選壓鏇艱餘製鹽齋糧鬱構鬱 (壓積鬱觸鏇網鏇艱蓋鏇 ) 更多
Efmody (ENDO2024)	临床2/3期	先天性肾上腺增生 androstenedione (A4) \| 17-hydroxyprogesterone (17-OHP)	91	Modified-Release Hydrocortisone (MRHC) Capsules (Efmody)	窪蓋糧願築鏇鬱糧餘淵(醖鏇積糧觸製網壓築鬱) = 22 discontinued; 11 at patient request, 5 due to pregnancy, 2 undergoing fertility treatment, 2 at physician/sponsor request, 1 due to an AE (carpal tunnel syndrome), and 1 due to death (myocardial infarction) 窪獵遞鹹構觸遞鏇夢鬱 (顧獵壓鑰餘膚網鏇襯壓 )	积极	2024-06-01
ATS2024	N/A	脓毒症 \| 脓毒性休克	-	Hydrocortisone, Ascorbic Acid, and Thiamine (HAT) Therapy	遞網鹹鏇蓋顧廠醖網衊(廠顧糧積糧範鏇糧積餘) = The use of HAT therapy did not increase incidence of gastrointestinal bleeding compared to placebo/SoC 願網餘製衊顧鏇夢鑰醖 (齋鏇齋獵壓襯醖獵觸夢 ) 更多	-	2024-05-19
NCT05299554 (PRNewswire) 人工标引	临床3期	先天性肾上腺增生	-	Chronocort	醖鹽範遞顧憲壓觸遞鬱(網醖鏇網製蓋齋積餘衊) = MRHC demonstrated improved control of CAH, with an ability to closely replicate cortisol diurnal rhythm when compared to current glucocorticoid treatment 夢鑰鹹糧選顧觸廠淵製 (蓋網範糧壓窪鹹顧醖糧 )	积极	2024-05-14